Protagenic Therapeutics

Protagenic Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is -5.83 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -5.70 M USD — a change of 2.29% (lower).

EBITDA

-5.83 MUSD

YoY

2.29%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Protagenic Therapeutics is 2025 -5.83 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Protagenic Therapeutics was 2024 -5.70 M USD. It decreases by 2.29% lower compared to the previous year.

The Protagenic Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.31 M USD
Jan 1, 2019
-2.09 M USD
Jan 1, 2020
-2.55 M USD
Jan 1, 2021
-4.14 M USD
Jan 1, 2022
-3.56 M USD
Jan 1, 2023
-4.53 M USD
Jan 1, 2024
-5.70 M USD
Jan 1, 2025
-5.83 M USD
The Protagenic Therapeutics EBITDA history
YEAREBITDAYoY
-5.83 MUSD+2.29%
-5.70 MUSD+25.93%
-4.53 MUSD+27.23%
-3.56 MUSD-14.06%
-4.14 MUSD+62.23%
-2.55 MUSD+22.34%
-2.09 MUSD-9.85%
-2.31 MUSD-2.16%
-2.37 MUSD+5.86%
-2.23 MUSD+354.99%
-491,000.00USD-49.64%
-975,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Protagenic Therapeutics is -5.83 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Protagenic Therapeutics changed from -5.70 M USD to -5.83 M USD, representing a 2.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Protagenic Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics